1. Home
  2. AZTR vs SYNX Comparison

AZTR vs SYNX Comparison

Compare AZTR & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

BUY

Current Price

$0.12

Market Cap

7.9M

Sector

Health Care

ML Signal

BUY

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

BUY

Current Price

$0.82

Market Cap

6.8M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
AZTR
SYNX
Founded
2014
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
6.8M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
AZTR
SYNX
Price
$0.12
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 628.4K
37.1K
Earning Date
11-11-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 5.06
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.10
$0.73
52 Week High
$1.09
$1.95

Technical Indicators

Market Signals
Indicator
AZTR
SYNX
Relative Strength Index (RSI) 31.49 38.54
Support Level $0.10 $0.79
Resistance Level $0.15 $1.09
Average True Range (ATR) 0.01 0.07
MACD -0.00 -0.02
Stochastic Oscillator 5.06 0.00

Price Performance

Historical Comparison
AZTR
SYNX

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.

Share on Social Networks: